Keyphrases
Type 2 Diabetic Patients
100%
Rosiglitazone
100%
Cardiovascular Outcomes
100%
Database Testing
100%
Confidence Interval
62%
Hazard Ratio
62%
Metformin
62%
Acute Coronary Syndrome
37%
All-cause Mortality
37%
Congestive Heart Failure
37%
Acute Myocardial Infarction
37%
Coronary Revascularization
37%
Meta-analysis
25%
Adverse Cardiovascular Events
25%
Type 2 Diabetes Mellitus (T2DM)
12%
Non-associated
12%
Health Maintenance Organizations
12%
Univariate Analysis
12%
Acute Myocardial Infarction Diagnosis
12%
Mortality Hazard
12%
Community-based Cohort
12%
Retrospective Observational Study
12%
Failure Hazard
12%
Online Treatment
12%
Type 2 Diabetes Mellitus Patients
12%
New Diagnosis
12%
Medicine and Dentistry
Cardiovascular System
100%
Patient with Type 2 Diabetes
100%
Rosiglitazone
100%
Hazard Ratio
71%
Acute Heart Infarction
57%
Glycon
57%
All Cause Mortality
42%
Congestive Heart Failure
42%
Heart Muscle Revascularization
42%
Acute Coronary Syndrome
42%
Maturity Onset Diabetes of the Young
28%
Meta-Analysis
28%
Observational Study
14%
Retrospective Study
14%
Univariate Analysis
14%
Metformin Plus Rosiglitazone
14%
Pharmacology, Toxicology and Pharmaceutical Science
Rosiglitazone
100%
Non Insulin Dependent Diabetes Mellitus
100%
Acute Heart Infarction
57%
Metformin
57%
All Cause Mortality
42%
Congestive Heart Failure
42%
Acute Coronary Syndrome
42%
Observational Study
14%
Retrospective Study
14%
Metformin Plus Rosiglitazone
14%